Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

ISRG vs ZBH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+134.6%
ZBH
Zimmer Biomet Holdings, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$16.32B
5Y Perf.-32.0%

ISRG vs ZBH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ISRG logoISRG
ZBH logoZBH
IndustryMedical - Instruments & SuppliesMedical - Devices
Market Cap$161.07B$16.32B
Revenue (TTM)$10.58B$8.41B
Net Income (TTM)$2.98B$761M
Gross Margin66.3%70.0%
Operating Margin30.5%15.6%
Forward P/E43.8x9.8x
Total Debt$303M$7.52B
Cash & Equiv.$3.37B$592M

ISRG vs ZBHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ISRG
ZBH
StockMay 20May 26Return
Intuitive Surgical,… (ISRG)100234.6+134.6%
Zimmer Biomet Holdi… (ZBH)10068.0-32.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: ISRG vs ZBH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ZBH leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Intuitive Surgical, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs ZBH's -17.8%
  • Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
Best for: growth exposure and long-term compounding
ZBH
Zimmer Biomet Holdings, Inc.
The Income Pick

ZBH carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 0 yrs, beta 0.65, yield 1.1%
  • Beta 0.65, yield 1.1%, current ratio 1.98x
  • Lower P/E (9.8x vs 43.8x)
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs ZBH's 7.2%
ValueZBH logoZBHLower P/E (9.8x vs 43.8x)
Quality / MarginsISRG logoISRG28.2% margin vs ZBH's 9.1%
Stability / SafetyZBH logoZBHBeta 0.65 vs ISRG's 1.02
DividendsZBH logoZBH1.1% yield; the other pay no meaningful dividend
Momentum (1Y)ZBH logoZBH-10.4% vs ISRG's -15.4%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs ZBH's 3.3%, ROIC 15.0% vs 5.4%

ISRG vs ZBH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
ZBHZimmer Biomet Holdings, Inc.
FY 2025
Knees
43.9%$3.3B
S E T
28.4%$2.2B
Hips
27.7%$2.1B

ISRG vs ZBH — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGZBH

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

ISRG and ZBH operate at a comparable scale, with $10.6B and $8.4B in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to ZBH's 9.1%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricISRG logoISRGIntuitive Surgica…ZBH logoZBHZimmer Biomet Hol…
RevenueTrailing 12 months$10.6B$8.4B
EBITDAEarnings before interest/tax$3.8B$2.3B
Net IncomeAfter-tax profit$3.0B$761M
Free Cash FlowCash after capex$2.8B$1.8B
Gross MarginGross profit ÷ Revenue+66.3%+70.0%
Operating MarginEBIT ÷ Revenue+30.5%+15.6%
Net MarginNet income ÷ Revenue+28.2%+9.1%
FCF MarginFCF ÷ Revenue+26.8%+21.8%
Rev. Growth (YoY)Latest quarter vs prior year+23.0%+9.3%
EPS Growth (YoY)Latest quarter vs prior year+18.8%+34.1%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ZBH leads this category, winning 6 of 6 comparable metrics.

At 23.5x trailing earnings, ZBH trades at a 59% valuation discount to ISRG's 57.6x P/E. On an enterprise value basis, ZBH's 9.5x EV/EBITDA is more attractive than ISRG's 43.6x.

MetricISRG logoISRGIntuitive Surgica…ZBH logoZBHZimmer Biomet Hol…
Market CapShares × price$161.1B$16.3B
Enterprise ValueMkt cap + debt − cash$158.0B$23.3B
Trailing P/EPrice ÷ TTM EPS57.62x23.48x
Forward P/EPrice ÷ next-FY EPS est.43.84x9.83x
PEG RatioP/E ÷ EPS growth rate2.65x
EV / EBITDAEnterprise value multiple43.62x9.47x
Price / SalesMarket cap ÷ Revenue16.00x1.98x
Price / BookPrice ÷ Book value/share9.17x1.30x
Price / FCFMarket cap ÷ FCF64.67x11.09x
ZBH leads this category, winning 6 of 6 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 8 of 8 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $6 for ZBH. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ZBH's 0.59x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs ZBH's 5/9, reflecting solid financial health.

MetricISRG logoISRGIntuitive Surgica…ZBH logoZBHZimmer Biomet Hol…
ROE (TTM)Return on equity+16.9%+5.8%
ROA (TTM)Return on assets+14.8%+3.3%
ROICReturn on invested capital+15.0%+5.4%
ROCEReturn on capital employed+16.5%+6.9%
Piotroski ScoreFundamental quality 0–965
Debt / EquityFinancial leverage0.02x0.59x
Net DebtTotal debt minus cash-$3.1B$6.9B
Cash & Equiv.Liquid assets$3.4B$592M
Total DebtShort + long-term debt$303M$7.5B
Interest CoverageEBIT ÷ Interest expense4.08x
ISRG leads this category, winning 8 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

ISRG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $5,268 for ZBH. Over the past 12 months, ZBH leads with a -10.4% total return vs ISRG's -15.4%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs ZBH's -14.4% — a key indicator of consistent wealth creation.

MetricISRG logoISRGIntuitive Surgica…ZBH logoZBHZimmer Biomet Hol…
YTD ReturnYear-to-date-19.3%-7.1%
1-Year ReturnPast 12 months-15.4%-10.4%
3-Year ReturnCumulative with dividends+49.6%-37.2%
5-Year ReturnCumulative with dividends+58.7%-47.3%
10-Year ReturnCumulative with dividends+554.2%-17.8%
CAGR (3Y)Annualised 3-year return+14.4%-14.4%
ISRG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

ZBH leads this category, winning 2 of 2 comparable metrics.

ZBH is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than ISRG's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricISRG logoISRGIntuitive Surgica…ZBH logoZBHZimmer Biomet Hol…
Beta (5Y)Sensitivity to S&P 5001.02x0.65x
52-Week HighHighest price in past year$603.88$108.29
52-Week LowLowest price in past year$427.84$79.83
% of 52W HighCurrent price vs 52-week peak+75.1%+77.0%
RSI (14)Momentum oscillator 0–10042.434.3
Avg Volume (50D)Average daily shares traded1.8M2.2M
ZBH leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates ISRG as "Buy" and ZBH as "Hold". Consensus price targets imply 37.3% upside for ISRG (target: $623) vs 17.4% for ZBH (target: $98). ZBH is the only dividend payer here at 1.15% yield — a key consideration for income-focused portfolios.

MetricISRG logoISRGIntuitive Surgica…ZBH logoZBHZimmer Biomet Hol…
Analyst RatingConsensus buy/hold/sellBuyHold
Price TargetConsensus 12-month target$622.60$97.90
# AnalystsCovering analysts5542
Dividend YieldAnnual dividend ÷ price+1.1%
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS$0.96
Buyback YieldShare repurchases ÷ mkt cap+1.4%+3.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ZBH leads in 2 (Valuation Metrics, Risk & Volatility).

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 3 of 6 categories
Loading custom metrics...

ISRG vs ZBH: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is ISRG or ZBH a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 5x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ISRG or ZBH?

On trailing P/E, Zimmer Biomet Holdings, Inc.

(ZBH) is the cheapest at 23. 5x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x.

03

Which is the better long-term investment — ISRG or ZBH?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -47. 3% for Zimmer Biomet Holdings, Inc. (ZBH). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus ZBH's -17. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ISRG or ZBH?

By beta (market sensitivity over 5 years), Zimmer Biomet Holdings, Inc.

(ZBH) is the lower-risk stock at 0. 65β versus Intuitive Surgical, Inc. 's 1. 02β — meaning ISRG is approximately 56% more volatile than ZBH relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 59% for Zimmer Biomet Holdings, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ISRG or ZBH?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc. grew EPS 22. 6% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ISRG or ZBH?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus 8. 6% for Zimmer Biomet Holdings, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus 16. 5% for ZBH. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ISRG or ZBH more undervalued right now?

On forward earnings alone, Zimmer Biomet Holdings, Inc.

(ZBH) trades at 9. 8x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 34. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ISRG: 37. 3% to $622. 60.

08

Which pays a better dividend — ISRG or ZBH?

In this comparison, ZBH (1.

1% yield) pays a dividend. ISRG does not pay a meaningful dividend and should not be held primarily for income.

09

Is ISRG or ZBH better for a retirement portfolio?

For long-horizon retirement investors, Zimmer Biomet Holdings, Inc.

(ZBH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), 1. 1% yield). Both have compounded well over 10 years (ZBH: -17. 8%, ISRG: +554. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ISRG and ZBH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ISRG is a mid-cap high-growth stock; ZBH is a mid-cap quality compounder stock. ZBH pays a dividend while ISRG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

ZBH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ISRG and ZBH on the metrics below

Revenue Growth>
%
(ISRG: 23.0% · ZBH: 9.3%)
Net Margin>
%
(ISRG: 28.2% · ZBH: 9.1%)
P/E Ratio<
x
(ISRG: 57.6x · ZBH: 23.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.